This study is a longitudinal, multicenter, single-blind, two-arm randomized controlled trial designed to evaluate the effectiveness of Multi-Modal Cognitive Processing Therapy (MMCPT) for individuals with posttraumatic stress disorder (PTSD). Participants will be randomly assigned to either the intervention group receiving MMCPT or a control group receiving treatment-as-usual (TAU). The intervention follows the standard CPT manual developed by Resick and consists of twelve weekly 90-minute individual sessions. The primary outcomes include PTSD symptom severity assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5). Secondary outcomes include sleep quality (actigraphy, PSQI), anxiety (STAI), depression (HDRS-17), remission rate, and posttraumatic growth (PTGI). Assessments will occur at baseline, mid-treatment, post-treatment, and at 3-, 6-, 9-, and 12-month follow-ups.
Aged between 20 and 65 years
Diagnosed with PTSD according to DSM-5 criteria
Score ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5)
Able to provide informed consent
Diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder
Current substance dependence or abuse within the past 6 months
Severe suicidal ideation or suicide attempt in the past 6 months
Cognitive impairment or neurological disorder affecting participation